Long-awaited data released today from a large clinical trial comparing catheter ablation with drug therapy in treating atrial fibrillation showed no significant benefit for ablation, according to Dr. Douglas Packer, who presented the findings today at the annual meeting of the Heart Rhythm Society in Boston.
The 2,204-patient trial, sponsored by the National Institutes of Health and industry players Medtronic (NYSE:MDT), Boston Scientific (NYSE:BSX), Abbott (NYSE:ABT) and Johnson & Johnson (NYSE:JNJ) unit BioSense Webster, focused on a primary composite endpoint of total mortality, disabling stroke, bleeding and cardiac arrest. When considering all patients as randomized, Packer said, the researchers saw no difference between the control and treatment arms.
Get the full story at our sister site, Drug Delivery Business News.
The post HRS 2018: Study questions benefit of ablation over drug therapy for atrial fibrillation appeared first on MassDevice.
from MassDevice https://ift.tt/2KOlSei
Cap comentari:
Publica un comentari a l'entrada